このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Biogen 将来の成長

Future 基準チェック /26

Biogen利益と収益がそれぞれ年間17.4%と2.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に14.7% 18.5%なると予測されています。

主要情報

17.4%

収益成長率

18.5%

EPS成長率

Biotechs 収益成長	24.7%
収益成長率	2.2%
将来の株主資本利益率	14.7%
アナリストカバレッジ	Good
最終更新日	21 Jun 2024

今後の成長に関する最新情報

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16

Recent updates

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

May 23

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Apr 29

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Jun 28

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued

Apr 14

Is Biogen (NASDAQ:BIIB) A Risky Investment?

Mar 27

業績と収益の成長予測

NasdaqGS:BIIB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	9,886	2,646	2,906	3,338	23
12/31/2025	9,560	2,257	2,794	3,082	30
12/31/2024	9,520	1,943	2,267	2,637	30
3/31/2024	9,663	1,167	1,284	1,645	N/A
12/31/2023	9,836	1,161	1,236	1,547	N/A
9/30/2023	9,993	1,462	1,026	1,360	N/A
6/30/2023	9,972	2,665	1,123	1,428	N/A
3/31/2023	10,105	3,131	1,421	1,678	N/A
12/31/2022	10,173	3,047	1,141	1,384	N/A
9/30/2022	10,363	2,865	2,173	2,398	N/A
6/30/2022	10,634	2,059	2,315	2,542	N/A
3/31/2022	10,820	1,450	2,773	3,033	N/A
12/31/2021	10,982	1,556	3,345	3,640	N/A
9/30/2021	11,101	1,546	2,107	2,435	N/A
6/30/2021	11,698	1,918	2,461	2,810	N/A
3/31/2021	12,604	3,012	3,149	3,532	N/A
12/31/2020	13,445	4,001	3,678	4,230	N/A
9/30/2020	14,263	5,082	5,841	6,557	N/A
6/30/2020	14,487	5,927	6,349	7,071	N/A
3/31/2020	14,422	5,879	6,282	7,086	N/A
12/31/2019	14,378	5,889	6,409	7,079	N/A
9/30/2019	14,233	5,396	6,384	7,014	N/A
6/30/2019	14,072	5,294	6,324	7,055	N/A
3/31/2019	13,812	4,667	5,382	6,190	N/A
12/31/2018	13,453	4,431	5,302	6,188	N/A
9/30/2018	13,234	3,187	4,855	5,811	N/A
6/30/2018	12,872	2,968	4,659	5,703	N/A
3/31/2018	12,594	2,964	4,671	5,773	N/A
12/31/2017	12,274	2,539	N/A	4,551	N/A
9/30/2017	11,839	3,486	N/A	4,615	N/A
6/30/2017	11,717	3,293	N/A	3,978	N/A
3/31/2017	11,533	3,480	N/A	3,807	N/A
12/31/2016	11,449	3,703	N/A	4,587	N/A
9/30/2016	11,416	3,885	N/A	4,046	N/A
6/30/2016	11,238	3,818	N/A	3,950	N/A
3/31/2016	10,936	3,695	N/A	3,999	N/A
12/31/2015	10,764	3,547	N/A	3,919	N/A
9/30/2015	10,565	3,599	N/A	3,609	N/A
6/30/2015	10,299	3,490	N/A	3,627	N/A
3/31/2015	10,128	3,277	N/A	3,570	N/A
12/31/2014	9,703	2,935	N/A	2,942	N/A
9/30/2014	9,028	2,509	N/A	2,878	N/A
6/30/2014	8,345	2,139	N/A	2,636	N/A
3/31/2014	7,647	1,916	N/A	2,271	N/A
12/31/2013	6,932	1,862	N/A	2,345	N/A
9/30/2013	6,384	1,697	N/A	1,984	N/A
6/30/2013	5,942	1,608	N/A	1,854	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BIIBの予測収益成長率 (年間17.4% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: BIIBの収益 ( 17.4% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: BIIBの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: BIIBの収益 ( 2.2% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: BIIBの収益 ( 2.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BIIBの自己資本利益率は、3年後には低くなると予測されています ( 14.7 %)。

Biogen 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

Consensus EPS estimates fall by 11%

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Consensus EPS estimates increase by 11%

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Recent updates

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Pomerantz LLP Announces Filing of a Class Action against Biogen Inc

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Consensus EPS estimates fall by 11%

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Full year 2023 earnings: EPS misses analyst expectations

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 11%

Biotech And Pharma Diversification Pays Off

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 23%

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Now 22% undervalued

Biogen Inc., Annual General Meeting, Jun 26, 2023

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Now 20% undervalued

Insider recently sold US$804k worth of stock

Insider notifies of intention to sell stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued

Is Biogen (NASDAQ:BIIB) A Risky Investment?

Now 21% undervalued after recent price drop

Executive VP exercised options and sold US$259k worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Executive VP exercised options and sold US$415k worth of stock

Biogen Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression